FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3183173575> ?p ?o ?g. }

• W3183173575 endingPage "105186" @default.
• W3183173575 startingPage "105186" @default.
• W3183173575 abstract "Pyrano[2,3-d]pyrimidine derivatives were synthesized by treating cyclic compounds containing active methylene group with aldehyde and malononitrile in butanol. The behavior of pyrano[2,3-d]pyrimidine towards some electrophlies namely triethylorthoformate followed by nitrogen nucleophiles as isobutylamine, urea, phenylthiourea, p-toluidine, o-phenylenediamine, o-aminophenol, 2-amino-4-methyl-pyridine and acetic acid with the aim of obtaining some interesting non-mixed heterocyclic compounds. All synthesized compounds to some extent have shown good antimicrobial activity against different microbial strains that had been extracted by inhibiting cell wall synthesis. Compound 5b showed the highest antibacterial activities against B. subtilis, S. aureus and E. coli. On the other hand compound 5 g exhibited the highest antibacterial and antifungal activities against P. aeruginosa and A. niger respectively. In addition, they explore cytotoxic potentialities against different cell lines via DNA intercalation and Top-II inhibition. The cytotoxic activities clarify the strong inhibitory activity of derivative 5a against HepG2 cells with IC50 = 2.09 μM, while HCT-116 cells were highly susceptible to derivative 5c with IC50 = 2.61 μM, in the meantime, derivative 5f showed pronounced negative impact against MCF-7 (IC50 = 2.43 μM) when compared with other prepared compounds. All derivatives exhibited higher anticancer activities than doxorubicin against the three cell lines except compound 2 against both HepG2 and MCF-7 and compound 5e against HepG2 cell lines. Compounds 5a, 5c and 5f potently intercalate DNA at IC50 values of 26.96, 27.13 and 29.86 µM respectively, which were more potent than doxorubicin (IC50 value of 31.27 µM). Moreover, compounds 5a, 5c and 5f exhibited very good Topoisomerase II inhibitory activities with IC50 values of 0.752, 0.791 and 0.776 µM respectively, that were more potent than that of doxorubicin (IC50 = 0.94 µM). For a great extent, the molecular modeling studies were in agreement with that of in vitro cytotoxicity activity, DNA binding and Top-II inhibition results." @default.
• W3183173575 created "2021-08-02" @default.
• W3183173575 creator A5066270766 @default.
• W3183173575 creator A5074213732 @default.
• W3183173575 creator A5077642545 @default.
• W3183173575 creator A5080280370 @default.
• W3183173575 creator A5087771737 @default.
• W3183173575 date "2021-10-01" @default.
• W3183173575 modified "2023-09-24" @default.
• W3183173575 title "Design, synthesis, molecular docking and in silico ADMET profile of pyrano[2,3-d]pyrimidine derivatives as antimicrobial and anticancer agents" @default.
• W3183173575 cites W1688725836 @default.
• W3183173575 cites W1813062314 @default.
• W3183173575 cites W1968469693 @default.
• W3183173575 cites W1969579048 @default.
• W3183173575 cites W1970557951 @default.
• W3183173575 cites W1981399953 @default.
• W3183173575 cites W1993716635 @default.
• W3183173575 cites W2006953370 @default.
• W3183173575 cites W2009867031 @default.
• W3183173575 cites W2013590640 @default.
• W3183173575 cites W2019759220 @default.
• W3183173575 cites W2023241595 @default.
• W3183173575 cites W2033392941 @default.
• W3183173575 cites W2039532349 @default.
• W3183173575 cites W2039568011 @default.
• W3183173575 cites W2044237788 @default.
• W3183173575 cites W2056202346 @default.
• W3183173575 cites W2057875903 @default.
• W3183173575 cites W2102345056 @default.
• W3183173575 cites W2106926141 @default.
• W3183173575 cites W2114918609 @default.
• W3183173575 cites W2127264662 @default.
• W3183173575 cites W2146014325 @default.
• W3183173575 cites W2151211514 @default.
• W3183173575 cites W2169092475 @default.
• W3183173575 cites W2169640519 @default.
• W3183173575 cites W2171216363 @default.
• W3183173575 cites W2623545481 @default.
• W3183173575 cites W2784709079 @default.
• W3183173575 cites W2793938485 @default.
• W3183173575 cites W2799299096 @default.
• W3183173575 cites W2970220863 @default.
• W3183173575 cites W3094082197 @default.
• W3183173575 cites W3102243945 @default.
• W3183173575 cites W3113558763 @default.
• W3183173575 cites W4241840908 @default.
• W3183173575 cites W4248107770 @default.
• W3183173575 doi "https://doi.org/10.1016/j.bioorg.2021.105186" @default.
• W3183173575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34314914" @default.
• W3183173575 hasPublicationYear "2021" @default.
• W3183173575 type Work @default.
• W3183173575 sameAs 3183173575 @default.
• W3183173575 citedByCount "32" @default.
• W3183173575 countsByYear W31831735752021 @default.
• W3183173575 countsByYear W31831735752022 @default.
• W3183173575 countsByYear W31831735752023 @default.
• W3183173575 crossrefType "journal-article" @default.
• W3183173575 hasAuthorship W3183173575A5066270766 @default.
• W3183173575 hasAuthorship W3183173575A5074213732 @default.
• W3183173575 hasAuthorship W3183173575A5077642545 @default.
• W3183173575 hasAuthorship W3183173575A5080280370 @default.
• W3183173575 hasAuthorship W3183173575A5087771737 @default.
• W3183173575 hasConcept C155647269 @default.
• W3183173575 hasConcept C159110408 @default.
• W3183173575 hasConcept C161790260 @default.
• W3183173575 hasConcept C178790620 @default.
• W3183173575 hasConcept C185592680 @default.
• W3183173575 hasConcept C202751555 @default.
• W3183173575 hasConcept C21951064 @default.
• W3183173575 hasConcept C2777752497 @default.
• W3183173575 hasConcept C2779321679 @default.
• W3183173575 hasConcept C2779485729 @default.
• W3183173575 hasConcept C2780104969 @default.
• W3183173575 hasConcept C2780513484 @default.
• W3183173575 hasConcept C41685203 @default.
• W3183173575 hasConcept C4937899 @default.
• W3183173575 hasConcept C523546767 @default.
• W3183173575 hasConcept C54355233 @default.
• W3183173575 hasConcept C55493867 @default.
• W3183173575 hasConcept C71240020 @default.
• W3183173575 hasConcept C71924100 @default.
• W3183173575 hasConcept C86803240 @default.
• W3183173575 hasConceptScore W3183173575C155647269 @default.
• W3183173575 hasConceptScore W3183173575C159110408 @default.
• W3183173575 hasConceptScore W3183173575C161790260 @default.
• W3183173575 hasConceptScore W3183173575C178790620 @default.
• W3183173575 hasConceptScore W3183173575C185592680 @default.
• W3183173575 hasConceptScore W3183173575C202751555 @default.
• W3183173575 hasConceptScore W3183173575C21951064 @default.
• W3183173575 hasConceptScore W3183173575C2777752497 @default.
• W3183173575 hasConceptScore W3183173575C2779321679 @default.
• W3183173575 hasConceptScore W3183173575C2779485729 @default.
• W3183173575 hasConceptScore W3183173575C2780104969 @default.
• W3183173575 hasConceptScore W3183173575C2780513484 @default.
• W3183173575 hasConceptScore W3183173575C41685203 @default.
• W3183173575 hasConceptScore W3183173575C4937899 @default.
• W3183173575 hasConceptScore W3183173575C523546767 @default.
• W3183173575 hasConceptScore W3183173575C54355233 @default.

• next